Abstract:Objective: To compare the effects of simvastatin and atorvastatin on hemostatic parameters. Methods: Sixty-one patients with primary hypercholesterolemia without coronary heart disease were treated with atorvastatin 10-20 mg/d or simvastatin 10-20 mg/d. At baseline, 4, 12, and 24 weeks, lipid levels such as low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), very-low-density lipoprotein cholesterol (VLDL-C), triglycerides (TGs), and hemostatic parameters such as platelet counts, partial thromboplastin time (PTT) prothrombin time (PT), and fibrinogen levels were measured. Results: At 12 weeks, the doses of the statins were increased to 20 mg/d in 10 of 35 (28.5%) patients treated with atorvastatin and 18 of 26 (69.2%) patients treated with simvastatin when the target level of LDL-C (130 mg/dL) was not reached. Mean doses were atorvastatin 12.8 mg/d and simvastatin 16.9 mg/d. After 24 weeks, 5 patients (14.3%) in the atorvastatin group and 4 patients (15.3%) in the simvastatin group had not reached the goal. In patients with diabetes, target level (LDL-C <100 mg/dL) was not reached in 35.7% of patients in the atorvastatin group and 44.4% of patients in the simvastatin group. Both simvastatin and atorvastatin were effective in lowering TC and LDL-C levels (p < 0.001). Atorvastatin lowered TGs significantly (p < 0.01). Neither atorvastatin nor simvastatin significantly reduced VLDL-C levels. HDL-C levels increased with atorvastatin, but there was no significant difference between the 2 groups. Platelet counts decreased with both statins nonsignificantly. Moreover, fibrinogen levels decreased with simvastatin and atorvastatin, but these reductions were significant only for simvastatin (p < 0.05). We detected prolongation of the PT with both drugs (p < 0.05); however, prolongation of the PTT was significant only with simvastatin (p < 0.001). Effectiveness of both statins on lipid and hemostatic parameters was dose related. Adverse effects were seen in 5 patients (14.2%) treated with atorvastatin and 3 patients (11.5%) treated with simvastatin. Elevations in serum transaminase levels >3 times the upper limit of normal and in creatine phosphokinase >5 times the upper limit of normal were not observed in any group. Conclusions: Atorvastatin was more effective than simvastatin on lipid parameters, although statistically insignificantly, while simvastatin produced more significant changes than atorvastatin on hemostatic parameters. The mean dose of simvastatin was greater than that of atorvastatin. Both statins had increased effects on lipid and hemostatic parameters when doses were increased. Atorvastatin and simvastatin were well tolerated. Different effects of statins on lipid levels and on coagulation parameters should be considered in patients with hypercholesterolemia and tendency to coagulation, especially in preventing thrombotic events. Further studies in larger trials are needed to confirm these observations.

Effects of Long-Term Treatment with Simvastatin on Some Hemostatic Parameters in Continuous Ambulatory Peritoneal Dialysis Patients

[Effects on Simvastatin in Continuous Ambulatory Peritoneal Dialysis Patients with Hyperlipidemia].

Effects of Simvastatin on Cardiac Performance and Expression of Sarco-Plasmic Reticular Calcium Regulatory Proteins in Rat Heart

Anti-myocardial Ischemic Effects of Simvastatin on Patients with Stable Angina Pectoris and Average Lipid Levels

Effects of Simvastatin on Blood Lipids, Von Willebrand Factor and Endothelin in Coronary Heart Disease

Effect of Simvastatin on Acute Coronary Syndrome Complicated with Atrial Fibrillation

Hemostatic effects of atorvastatin versus simvastatin

Effectiveness and Safety of Simvastatin 40 mg Daily Use in Treatment of Coronary Heart Disease

Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects

Effects of Simvastatin on Serum Matrix Metalloproteinases-9 and C-reactive Protein Levels in Patients of Coronary Heart Disease

Effect of Simvastatin on Lipids and Lipid Ratios of the Elderly Patients with Coronary Heart Disease

Effect of Simvastatin on Serum Level of Inflammatory Factors in Acute Coronary Syndrome

Inhibition of Platelet Aggregation and Expression of Alpha Granule Membrane Protein 140 and Thromboxane B2 with Pravastatin Therapy for Hypercholesterolemia.

Effects of Simvastatin on Blood Levels of Inflammatory Cytokines in Patients with Unstable Angina Post Percutaneous Coronary Intervention

Efficacy of simvastatin on carotid atherosclerotic plaque and its effects on serum inflammatory factors and cardiocerebrovascular events in elderly patients

Effects of simvastatin on the number and adhesiveness of endothelial progenitor cells from umbilical vein blood cultured in vitro

Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects

The effects of enhanced blood lipid regulating therapy on atherosclerosis in maintenance hemodialysis patients

Effects on simvastatin on the atherosclerotic plaques of carotid artery in elderly patients with normal lipidenia level

Effects of statin therapy on mean platelet volume in patients with risk of cardiovascular diseases: a systematic review and meta-analysis.

Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients